GE develops and provides technology that enables pharmaceutical companies, clinicians and academic researchers to develop new therapies. This research includes the study, manipulation and storage of stem cells as a resource for drug discovery and manufacturing of cell-based therapies. GE uses pluripotent stem cells derived from both embryonic and adult sources for the development of predictive drug-screening applications and for technologies supporting the development and manufacture of cell therapies. GE Healthcare’s cell therapy division also offers technology for efficient and reproducible processing of umbilical cord blood in adult stem cell processing. GE recognizes the sensitivities associated with the use of some types of stem cells.
Cell therapies and immunotherapies are changing the face of medicine, enabling doctors to address not just the symptoms of a disease, but also its underlying causes, essentially teaching the body to heal itself. The pace of current developments in cell therapy and immunotherapy is promising, with some researchers reporting unprecedented clinical outcomes. However, the field still has many issues to overcome, and GE’s tools and technologies are helping customers make these new therapies affordable and part of mainstream clinical practice.
GE has ongoing and planned research that uses both adult-derived stem cells and established ES (embryonic stem) cell lines to develop drug research technologies and cell-based therapy applications.
GE conducts research in accordance with U.S. federal guidelines, as well as with the U.K.’s, and any other applicable country’s, legislation and recommendations regarding stem cell research. Our ES cell research programs employ established ES cell lines approved by the National Institutes of Health or other cell lines established in accordance with good ethical practice. GE will not be associated with the primary harvest of human embryo–derived cells or tissues for its research.
In a rapidly evolving scientific field, our intention is for GE’s position to accurately reflect the most recent government and public opinions, therefore, from time to time, we will update this statement to reflect such changes. This statement was last revised in January 2017.
We acknowledge the considerable debate over, and take very seriously the ethical and societal issues associated with, research using stem cells derived from embryonic or fetal tissue. We conduct our research in an ethically and scientifically responsible manner.